Scientists studied Association of Antiretroviral Therapy with Bone Loss in HIV Patients

Primary tabs

Scientists studied Association of Antiretroviral Therapy with Bone Loss in HIV Patients

Anti-retroviral therapy has led to a significant decline in mortality of individuals infected with human immunodeficiency virus (HIV). According to latest HIV treatment guidelines, antiretroviral treatment (ART) should be initiated at the time of diagnosis. A recent study has revealed that early ART can cause more significant bone loss compared with deferring ART.
This study followed 399 participants (195 received immediate ART and 204 deferred ART) for an average of 2.2 years.
The study determined an adverse effect on bone density in patients on immediate ART. But the overall benefits of ART for preventing HIV transmission and adverse health outcomes outweighs this adverse effects.

It is essential to study the long-term results of the association of reduced bone mineral density and ART. To understand whether these reductions continue or stabilise with more prolonged therapy.

Prof. Jennifer Hoy, lead author of the study said "What we found was that starting therapy is also correlated with accelerated bone loss of about 2-4%, and the rate of decline then seems to slow after the first 2 years of treatment, compared with HIV positive people who deferred therapy,".

"We have no remedy for HIV, so antiretroviral therapy is for life. An increased rate of bone loss may become essential years later, in the setting of increased risk of fragility fracture.'



Link to the source:

Original title of article:

Early antiretroviral therapy linked with bone loss in patients with HIV


Veronese N, Stubbs B  et al.

Therapeutic, HIV, Bone loss, Human, Anti-retroviral therapy, Fragility fracture.
Log in or register to post comments